A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis

Trial status: Authorised Proportion of participants achieving Itch NRS4 at Week 24, Proportion of participants achieving IGA CPG S-TS at Week 24, Proportion of participants achieving Itch NRS4 at Week 4 Proportion of participants achieving Itch NRS4 (≥ 4-point improvement [reduction] in Itch NRS score from baseline) and IGA-CPG-S-TS (IGA CPG-S score of 0 or 1 with a ≥ 2-grade improvement from baseline) at Week 24

Proportion of participants achieving Itch NRS4 at Week 24, Proportion of participants achieving IGA CPG S-TS at Week 24, Proportion of participants achieving Itch NRS4 at Week 4

Age group: 18-64 years, 65+ years Gender: Female, Male Target enrollment: 162 participants